INER owns a clinical-stage specialty for the research and development of radionuclide tracer in disease diagnostic and therapy. Radiopharmaceuticals approved by TFDA supply more than for 50 hospitals for various clinical applications. In recent years, according to the domestic demand and international development trends, INER actively developed radiopharmaceuticals, such as INER MIBG <I-123> Injection, to collaborate with domestic hospitals in clinical usage to benefit people.
INER MIBG <I-123> Injection is developed by INER as a radiopharmaceutical for diagnosis. INER delivered the registration of INER MIBG <I-123> Injection to TFDA in September 2017 and obtained letter of approval in August 5, 2019. INER had further received drug license from TFDA in September 4, 2019.
The indications for radionuclide tracer INER MIBG <I-123> Injection was as followed: 1. The detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests. 2. Evaluation of cardiac sympathetic nerve function by radioactive uptake ratio of Heart to Mediastinum (H/M) for Congestive Heart Failure.
As a leading radiopharmaceutical technology research and development institute in Taiwan, INER has constructed a platform of nuclear medicine development, molecular imaging, targeting therapy, radiopharmaceutical production, and human resource for further collaborating with academia, industry research institute and medical cancer in the future. INER will keep on developing innovative new diagnostic and therapeutic solutions approved by TFDA for domestic hospitals and taking responsibility for improving medical standard and take care of people’s health.